The bill aims to preserve seniors’ freedom of pharmacy choice by confronting tactics that bar pharmacies from Part D networks and drive pharmacies out of business.
Pemrydi is the first ready-to-use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
The injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to specific factors.